Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin

capecitabine plus bevacizumab

  • Open Access
    Phase II Trial of Capecitabine Plus Bevacizumab for Elderly Patients With Metastatic Colorectal Cancer: OGSG 1102
    TOSHIFUMI YAMAGUCHI, MOTOKI YOSHIDA, KOICHI TAIRA, SHINYA TOKUNAGA, TAKESHI KATO, MASATO NAKAMURA, NAOTOSHI SUGIMOTO, SOICHI FUMITA, MASAYOSHI YASUI, YASUHIRO MIYAKE, HISATO KAWAKAMI, YUKINORI KUROKAWA, TOSHIO SHIMOKAWA and TAROH SATOH
    In Vivo May 2025, 39 (3) 1505-1513; DOI: https://doi.org/10.21873/invivo.13950
In Vivo

© 2026 In Vivo

Powered by HighWire